



Kallistatin, IL-10, IL-1 β and hsCRP in the diagnosis of non-alcoholic fatty disease on the background of hypertension



Anastasiia Rozhdestvenska, PhD student; Natalia Zhelezniakova, MD, D.M.Sc., prof.
Department of Internal Medicine #1 in Kharkiv National Medical University (Kharkiv, Ukraine)

BACKGROUND

Non-alcoholic fatty liver disease (NAFLD) affects 25% of the adult population and often develops in comorbidity with hypertension (HT).

25%

ROC-analysis allow to assess the diagnostic potential of biomarkers for liver fibrosis detection in NAFLD patients.


OBJECTIVE

To evaluate the kallistatin (KS), IL-10, IL-1 β and hsCRP role in determining of development and progression of liver fibrosis in NAFLD and HT patients.

METHODS

63 patients with NAFLD on steatohepatitis stage and HT and 52 patients with isolated NAFLD were observed. Kallistatin, IL-10, IL-1 β and hsCRP levels were determined by enzyme-linked immunosorbent assay.

■ NAFLD + HT
■ NAFLD



RESULTS

The kallistatin showed significant potential in diagnosing the occurrence and progression of liver fibrosis in patients with NAFLD and HT and with isolated NAFLD. IL-10 and IL-1 β showed good prognostic characteristics for liver fibrosis progression detection in both groups of patients, and the hsCRP revealed prognostic abilities only in NAFLD and HT patients (table 1).

Table 1. Characteristics of ROC curves for the determination of biomarkers in the examined patients

	Marker	AUC	Sensitivity	Specificity	p
NAFLD + HT	KS	0.975/0.881	95%/95%	100%/77%	0.003/<0.001
	IL-10	0.772/0.710	75%/70%	75%/64%	0.314/0.009
	IL-1 β	0.600/0.752	90%/72%	50%/75%	0.535/0.002
	hsCRP	0.725/0.849	95%/80%	75%/85%	0.163/<0.001
NAFLD	KS	0.867/0.889	77%/92%	81%/83%	0.001/<0.001
	IL-10	0.562/0.769	81%/94%	35%/69%	0.518/0.012
	IL-1 β	0.517/0.788	71%/85%	48%/67%	0.860/0.007
	hsCRP	0.601/0.652	65%/69%	52%/56%	0.291/0.155

Simultaneous determination of all biomarkers allowed to predict the occurrence and progression of liver fibrosis in NAFLD and HT (AUC=1.000, p=0.002, Se=100%, Sp=100%; AUC=0.874, p<0.001, Se=82.1%, Sp=85.0%), and isolated NAFLD patients (AUC=0.874, p<0.001, Se=94.1%, Sp=71.4%, AUC=0.889, p<0.001, Se=84.6%, Sp=94.4%) (fig.1).




Figure 1. Characteristics of ROC curves for the simultaneous determination of all biomarkers

CONCLUSIONS

Kallistatin, IL-10, IL-1 β , and hsCRP levels determination can detect liver fibrotic changes in NAFLD and HT patients may be an alternative to invasive diagnostic methods.